NCT03183947 (APIC-II) is a NA clinical trial of fMRI in Depression, sponsored by RWTH Aachen University.

Who is sponsoring NCT03183947?

NCT03183947 is sponsored by RWTH Aachen University.

What drugs are being tested in NCT03183947?

Interventions in NCT03183947: fMRI, Neurofeedback, PANAS, BDI-II, ERQ.

What condition does NCT03183947 study?

NCT03183947 studies Depression, Schizophrenia.

Is NCT03183947 still recruiting?

NCT03183947 is currently completed. Last updated 10 December 2019.

Last reviewed 2019-12-10 · How we verify

NCT03183947: APIC-II

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Symptom Based Treatment Affects Brain Plasticity - Cognitive Training in Patients With Affective Symptoms

Completed NA Last updated 10 December 2019

What this trial tests

NA trial testing fMRI in Depression in 81 participants. Completed in 6 December 2019.

Timeline

29 August 2017

Primary endpoint
6 December 2019

6 December 2019

Quick facts

Lead sponsor	RWTH Aachen University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	81
Start date	29 August 2017
Primary completion	6 December 2019
Estimated completion	6 December 2019
Sites	1 location across Germany

Drugs / interventions tested

fMRI — full drug profile →
Neurofeedback
PANAS
BDI-II
ERQ

Conditions studied

Depression — all drugs for Depression →
Schizophrenia — all drugs for Schizophrenia →

Sponsor

RWTH Aachen University

Who can join

Adults 18 to 75, any sex, with Depression or Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is the examination of brain plasticity on on affective symptoms after neuromodulation with fMRI (functional magnetic resonance imaging) neurofeedback. During the fMRI neurofeedback training, patients with depression as well as patients with schizophrenia are trained to consciously regulate the activity of areas which are associated with the cognitive reappraisal of emotional stimuli.The aim is to improve the patients' subjective emotional processing and perception in everyday life as well as to investigate the impact of neurofeedback on resting-state networks in the brain. Healthy participants will be investigated as control group.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

fMRI Neurofeedback-Enhanced Cognitive Reappraisal Training in Depression: A Double-Blind Comparison of Left and Right vlPFC Regulation.
Keller M, Zweerings J, Klasen M, Zvyagintsev M, et al · · 2021 · cited 25× · PMID 34497546 · DOI 10.3389/fpsyt.2021.715898
Basic stimulus processing alterations from top-down cognitive control in depression drive independent temporal components of multi-echo naturalistic fMRI data.
Feng T, Gaebler AJ, Keller M, Zweerings J, et al · · 2025 · cited 1× · PMID 40379640 · DOI 10.1038/s41398-025-03386-4

Verify or expand the search:

Other trials of fMRI

Trials testing the same drug.

NCT06593470 — Mindfulness-Based Substance Use Prevention (MINDS-UP) · NA · not yet recruiting
NCT07259902 — FMRI Study on DC/TMD Patients · NA · not yet recruiting
NCT05524493 — High-field MR Imaging in Migraine, Visual Snow and Epilepsy · recruiting
NCT06673303 — Investigating The Role of Noise Correlations in Learning · NA · recruiting
NCT06467292 — Speech Motor Learning and Retention (Master Protocol) · NA · recruiting

Other recruiting trials for Depression

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting

Other RWTH Aachen University trials

Trials by the same sponsor.

NCT06390384 — Prevention Programme for Improvement of Well-being and Level of Participation in Adolescents With Enhanced Psychiatric B · NA · not yet recruiting
NCT07322796 — Smoking Cessation Before Bronchoscopy or CT-guided Puncture · recruiting
NCT04996914 — Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma · NA · not yet recruiting
NCT07053956 — Impact of Chewing Gum on FeNO Levels in Patients With Bronchial Asthma · NA · completed
NCT07140536 — The Impact of Treadmills and Cooler Environments for Office Workplaces on Ergonomics, Heating Energy Requirements, Perfo · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03183947 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RWTH Aachen University
Last refreshed: 10 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03183947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing